Mode
Text Size
Log in / Sign up
N/A N=33 Supportive Care

Anxiety Lowering and Deprescribing Through Emotion Regulation

Benzodiazepine Dependence · Anxiety Disorders · Sleep Disturbance

Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: Feasibility of Intervention — 67; 48 Percentage of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
ALDER (Behavioral)
Age
Older Adult · 65+ yrs
Sex
All
Sponsor
Northwestern University
Primary completion
Sep 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Feasibility of Intervention
67; 48
PRIMARY
Acceptability of Intervention
3.72
PRIMARY
Adoption of Intervention
4
SECONDARY
Patient Benzodiazepine Receptor Agonist (BZRA) Use
6; 5
SECONDARY
Patient-reported Sleep Disturbance
54.39; 52.79
SECONDARY
Patient-reported Anxiety
58.47; 57.49
SECONDARY
Patient-reported Stress
5.55; 4.94
SECONDARY
Patient-reported Depression
53.58; 52.52
SECONDARY
Patient-reported Positive Affect
41.42; 42.31
SECONDARY
Patient-reported Meaning and Purpose
45.51; 48.23

Summary

The goal of this clinical trial is to test ALDER (Anxiety Lowering and Deprescribing through Emotion Regulation), an online self-guided positive emotion intervention, in patients over the age of 65 who are candidates for benzodiazepine receptor agonist (BZRA, commonly called benzos, or z-drugs) deprescribing. The main questions it aims to answer are: * Is ALDER relevant to and satisfactory for older adult BZRA users? * Does ALDER help to increase positive emotions and decrease anxiety, trouble sleeping, and use of BZRA medications? Participants will complete the 5-week online self-guided ALDER intervention as well as two survey assessments, one before the intervention and one after.

Eligibility Criteria

Inclusion Criteria

  • Age 65 and over.
  • ≥1 NM Internal Medicine clinic visit within the past year.
  • BZRA prescribed by NM primary care within the past year.
  • Takes BZRA at least twice a week.
  • Daily access to internet-connected device.
  • Ability to read and speak English.

Exclusion Criteria

  • Dementia, seizure, or REM sleep disorder diagnosis.
  • In hospice care.
  • No daily internet access.
  • Cannot speak and read English.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06359314). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search